Baxter’s Ipump returns
This article was originally published in The Gray Sheet
Executive Summary
Firm will resume sales of Ipump pain management infusion pumps in the second quarter after announcing 510(k) clearance of an upgraded version Feb. 6. Baxter had placed Ipump "on hold" in July 2005 while it developed hardware and software to reduce error codes and improve programming. The firm is making similar improvements to its Colleague and Syndeo infusion pumps. The latter malfunction-prone devices have been off the market since a seizure by FDA in October 2005, followed by a June consent decree forbidding their sale until Baxter gets its manufacturing system back into compliance. The firm announced a 510(k) filing for an updated Colleague and approval of a corrective action plan in December (1"The Gray Sheet" Dec. 18, 2006, In Brief)...
You may also be interested in...
Baxter’s Colleague moves ahead
Firm announces conditional FDA approval on Dec. 14 of a corrective action plan for the Colleague drug infusion pump. The company also reported filing an updated 510(k) for the device. Upon agency clearance of the 510(k) and final approval of the corrective plan, Baxter will begin field upgrades to more than 200,000 pumps in U.S. hospitals. The pumps have been off the market for more than a year, following an October 2005 seizure by FDA. In June Baxter signed a consent decree with the agency requiring the firm to comply with manufacturing quality control regulations before U.S. sales can resume (1"The Gray Sheet" July 3, 2006, p. 4)...
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.